Summary
Definition
History and exam
Key diagnostic factors
- presence of risk factors
- Raynaud's phenomenon (RP)
- dysphagia
- GORD
- dilated nailbed capillaries
- bright shiny skin of hands, feet
- symmetrical swelling, tight fingers
- prayer sign
- claw hand deformities
- ulcers on fingers
- flexion contracture of hands
- carpal tunnel syndrome
- calcinosis
- large well-demarcated telangiectasia
Other diagnostic factors
- skin pigmentation changes
- family history of connective tissue disease
Diagnostic investigations
1st investigations to order
- full blood count
- serum creatinine
- serum antinuclear antibody
- serum extractable nuclear antigens
- serum erythrocyte sedimentation rate (ESR)
- echocardiogram
- pulmonary function tests (PFTs)
Investigations to consider
- peripheral blood smear
- anti-centromere antibody
- high-resolution CT chest
- oesophageal manometry
Treatment algorithm
Contributors
Authors
Janet E. Pope, MD, MPH, FRCPC

Professor of Medicine
Division of Rheumatology
Department of Medicine
Schulich School of Medicine and Dentistry
University of Western Ontario
Head
Division of Rheumatology
St. Joseph's Health Care
London
Ontario
Canada
Disclosures
JEP has consulted for and/or performed research trials with AbbVie, Amgen, AstraZeneca, BI, BMS, Fresenius Kabi, Galapagos, GSK, Janssen, Lilly, Merck, Novartis, Organon, Pfizer, Roche, Sandoz, Sanofi, United Chemicals Belgium, Horizon, Mallinckrodt, and Viatris. JEP is an author of several references cited in this topic.
Peer reviewers
Virginia Steen, MD
Professor of Medicine
Georgetown University
Washington
DC
Disclosures
VS has received research funding, consulting fees, and honorarium from Actelion and Gilead, which could result in competing interests. VS is an author of several references cited in this topic.
Frank Wollheim, MD
Emeritus Professor
Department of Rheumatology
Lund University Hospital
Lund
Sweden
Disclosures
FW is an author of a reference cited in this topic.
Gabriela Riemekasten, PD, Dr. med.
Charité-Universitätsmedizin Berlin
Medizinische Klinik mit Schwerpunkt
Rheumatologie und Klinische Immunologie
Charitéplatz
Berlin
Germany
Disclosures
GR is a consultant for Encysive, Actelion, Bayer, GSK, Roche, and other companies, and received lecture fees from all of these companies involved in systemic scleroderma. GR is an author of a reference cited in this topic.
References
Key articles
Mayes MD, Lacey JV Jr., Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003 Aug;48(8):2246-55.Full text Abstract
Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford). 2016 Oct;55(10):1906-10.Full text Abstract
van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov;72(11):1747-55.Full text Abstract
Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327-39.Full text Abstract
Walker KM, Pope J; participating members of the Scleroderma Clinical Trials Consortium (SCTC), Canadian Scleroderma Research Group (CSRG). Treatment of systemic sclerosis complications: what to use when first-line treatment fails - a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42:42-55. Abstract
Reference articles
A full list of sources referenced in this topic is available here.
Use of this content is subject to our disclaimer